Furich Pharmaceuticals expects first quarter net profit to increase 2222.67% to 3250.01% year-over-year

NightAirdropper · 2026-03-24T02:12:36+00:00

Fuxiang Pharmaceuticals expects its net profit in the first quarter of 2026 to reach between 52 million and 75 million yuan, representing a year-over-year increase of 2222.67% to 3250.01%. Benefiting from the rapid development of the new energy industry, the company's demand for lithium battery materials continues to grow. In the future, the company will strengthen its presence in the pharmaceutical market, expand its new energy production capacity, and promote the construction of its microbial protein project.

NightAirdropper

2026-03-24 02:12:36

Abstract generation in progress

Beijing Business Daily (Reporter Ding Ning) reported that on the evening of March 23, Fuxiang Pharmaceutical (300497) announced its first-quarter 2026 earnings forecast, expecting a net profit attributable to shareholders of 52 million to 75 million yuan, a year-on-year increase of 2222.67% to 3250.01%.

Fuxiang Pharmaceutical stated that during the reporting period, benefiting from the continued improvement in the new energy industry, steady growth in demand for power batteries, and rapid explosion in demand for energy storage batteries, upstream lithium battery materials demand continued to rise. The company’s lithium battery electrolyte additive business performed well, with core products such as VC and FEC experiencing simultaneous increases in volume and price, driving significant year-on-year growth in performance.

Fuxiang Pharmaceutical also said that by 2026, the pharmaceutical sector will consolidate its market advantage and focus on cost reduction and efficiency improvement; the new energy sector will seize market opportunities through technological transformation to expand capacity and ensure supply; in the synthetic biology sector, the company will accelerate the construction and capacity release of the microbial protein (Wei Ran protein) project, expand application scenarios, and develop markets domestically and internationally.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes